Skip to main content
Ir a la página de inicio de la Comisión Europea (se abrirá en una nueva ventana)
español es
CORDIS - Resultados de investigaciones de la UE
CORDIS

In vivo validation of a novel, high precision Positive Allosteric Modulation-based therapy for immune-inflammatory diseases

Objetivo

Immune-inflammatory diseases arise when the balance between stimulatory and inhibitory checkpoint signals is disrupted, causing excessive immune responses and ultimately breaking immune tolerance and tissue homeostasis. Current therapies either broadly suppress the immune system or block stimulatory checkpoints, but none exploit the activity of inhibitory checkpoints as a mechanism built by nature to restore immune homeostasis. This leaves a clear therapeutic gap, and an opportunity to locally control immune responses while avoiding systemic immunosuppression.

Within my ERC-2023-ADG, we discovered VHH-based positive allosteric modulators (PAMs) that activate different inhibitory checkpoints rather than blocking them. These PAMs stabilize the native receptor–ligand interaction in vitro and stimulate intracellular signalling with, as a unique feature, ligand dependent and spatio temporal precision. An in vivo proof-of-concept is essential to bridge the translational gap towards their therapeutic application.

To consolidate our PAMs as a new modality for restoring immune checkpoint signalling in immune inflammatory diseases, we will (i) confirm target engagement by PAMs ex vivo using human samples; (ii) deliver in vivo proof of mechanism for inhibitory immune checkpoint PAMs in a Graft-versus-Host-Disease mouse model and (iii) evaluate further developed PAM formats to enhance the impact of the therapeutic effects.

These PoC data will provide the momentum needed to launch Allosteris -our next spin-off in the field of allosteric immunotherapies- by strengthening our IP, derisking the technology, and expanding partnering opportunities. In essence, this ERC PoC grant will sharpen Allosteris’ unique value proposition by advancing a therapeutic strategy that restores inhibitory immune signalling rather than applying blanket immunosuppression, paving the way for safer, precision treatments for immune-inflammatory diseases.

Ámbito científico (EuroSciVoc)

Programa(s)

Tema(s)

Régimen de financiación

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

Ver todos los proyectos financiados en el marco de este régimen de financiación

Convocatoria de propuestas

(se abrirá en una nueva ventana) ERC-2026-POC

Ver todos los proyectos financiados en el marco de esta convocatoria

Institución de acogida

VIB VZW
Aportación neta de la UEn
€ 150 000,00
Dirección
SUZANNE TASSIERSTRAAT 1
9052 ZWIJNAARDE - GENT
Bélgica
Región
Vlaams Gewest Prov. Oost-Vlaanderen Arr. Gent
Tipo de actividad
Research Organisations
Enlaces
Coste total
Sin datos

Beneficiarios (1)